India’s pharmaceutical sector is rapidly shifting from a generics-led foundation to an innovation-driven ecosystem, with growing emphasis on biosimilars, peptides, complex generics, and next-generation biologics.
“This transition is being accelerated by government and CDSCO reforms such as streamlined approvals, reduced regulatory layers, decriminalisation of non-serious offences, and the recommendation of R&D projects worth Rs 5,000 crore,” said Dr. R Chandrashekar, Joint Drugs Controller, The Central Drugs Standard Control Organisation (CDSCO).
With these measures, India is well-positioned to evolve from being the pharmacy of the world to an innovation-led pharma nation over the next five years, he said.
According to Namit Joshi, Chairman, Pharmaceuticals Export Promotion Council of India (Pharmexcil), “The global pharmaceutical landscape is shifting rapidly, and India must evolve beyond its traditional generics mindset to remain the pharmacy of the world.”
The future lies in value-driven innovation—advancing capabilities in peptides, complex generics, biosimilars, biologics, targeted drug delivery systems, and cell and gene therapies, Joshi said while speaking at the 18th edition of CPHI & PMEC India, organised by Informa Markets in India.
———